Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Recommendations of the Coronavirus Study Group for the Nomenclature of the Structural Proteins, mRNAs, and Genes of Coronaviruses

D. CAVANAGH, D. A. BRIAN, L. ENJUANES, K. V. HOLMES, M. M. C. LAI, H. LAUDE, S. G. SIDDELL, W. SPAAN, F. TAGUCHI, AND P. J. TALBOT

Division of Molecular Biology, AFRC Institute for Animal Health, Houghton Laboratory, Huntingdon, Cambridgeshire PE 17 2DA, United Kingdom; Department of Microbiology, University of Tennessee, Knoxville, Tennessee 37996-0845; Centro de Biologia Molecular (CSIC-UAM), Universidad Autonoma, Canto Blanco, 28049 Madrid, Spain; Department of Pathology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, Maryland 20814-4799; Department of Microbiology, USC School of Medicine, 411 Zonal Avenue, Los Angeles, California 90033-1034; INRA, Station de Recherches de Virologie et d’Immunologie Moléculaire, Centre de Recherches de Jouy-en-Josas, Domaine de Vilvert, 78350 Jouy-en-Josas, France; Institut für Virologie und Immunbiologie der Universität Würzburg, Versbacher Strasse 7, 8700 Würzburg, West Germany; Institute of Infectious Disease & Immunology, Virology Department, State University of Utrecht, Vleutenlaan 1, P.O. Box 80165, 3508 TD Utrecht, The Netherlands; National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187, Japan; and Institut Armand-Frappier, Université du Québec, Virology Research Centre, Ville de Laval, Québec, Canada H7N 4Z3

Received November 22, 1989; accepted November 28, 1989

We propose a nomenclature to replace the various systems currently in use to designate coronavirus structural proteins, mRNAs, and genes/open reading frames. The nonstructural proteins have not been addressed.

Several names are currently used to refer to each of the three or four structural proteins of coronaviruses, with corresponding and different acronyms. Similarly, the mRNAs (reviewed in Refs. (1) and (2)) have been referred to by numbers or by letters. Finally, the genes/open reading frames (ORFs) have been designated by different authors in several different ways.

To overcome the confusion thus created, the Coronavirus Study Group of the Vertebrate Virus Subcommittee of the International Committee on Taxonomy of Viruses has reviewed the situation. At the Fourth International Symposium on Coronaviruses, held in July 1989 at King’s College, Cambridge, England, the Group recommended a revised nomenclature to be used for all coronaviruses. The guidelines that have been formulated, if followed, will allow for newly identified mRNAs, genes, or ORFs to be named without creating confusion. The Study Group considered it inappropriate to make recommendations regarding proteins that are believed to be nonstructural because at the moment information is limited.

STRUCTURAL PROTEINS

The recommended acronyms for the structural proteins are shown in Table 1. The virion proteins have recently been reviewed (2).

* To whom requests for reprints should be addressed.

The large surface projection (spike or peplomer glycoprotein) has previously been referred to as S (3) or E2 (4). The acronym S may be used to denote the primary translation product and generally to refer to the spike glycoprotein. In some, though not all, coronaviruses, S is cleaved into two glycopolyptides, the amino (N)-terminal S1 (E2B) and the carboxy (C)-terminal S2 (E2A) glycopolyptides (the previous alternative acronyms are shown in parentheses (5)). The hemagglutinin–esterase (HE) glycoprotein has frequently been referred to by its approximate molecular weight, i.e., about 65,000 and 140,000 in its reduced and nonreduced forms, respectively, and more recently by the acronyms E3, H, and HA. Those coronaviruses which cause hemagglutination but do not have the HE protein (e.g., infectious bronchitis virus (IBV), transmissible gastroenteritis virus) have poor hemagglutination activity. In contrast, those viruses with good hemagglutination activity do have the HE protein, although the presence of HE does not necessarily mean that the virus causes hemagglutination activity. In contrast, those viruses with good hemagglutination activity do have the HE protein, although the presence of HE does not necessarily mean that the virus causes hemagglutination activity. In contrast, those viruses with good hemagglutination activity do have the HE protein, although the presence of HE does not necessarily mean that the virus causes hemagglutination activity. In contrast, those viruses with good hemagglutination activity do have the HE protein, although the presence of HE does not necessarily mean that the virus causes hemagglutination activity.
navirus is a receptor-destroying enzyme with acetylsterase activity (7).

The Study Group has recommended that the integral membrane glycoprotein, M (previously also designated E1 (4)), should not be referred to as a matrix protein. The structure of this protein is substantially different from that of the matrix proteins of para- and orthomyxoviruses. The nucleocapsid (N) protein is sometimes referred to as the nucleoprotein, with the same acronym.

mRNAs

mRNAs are to be referred to by numbers 1, 2, 3... in order of decreasing size. The genome-sized mRNA is therefore mRNA 1. Consequently, the mRNAs of IBV, previously denoted as F, E, D, C, B, and A (8), should henceforth be referred to as 1, 2, 3, 4, 5, and 6, respectively.

 Coronaviruses differ in the number of their subgenomic mRNAs. It is recognized that mRNAs of different coronaviruses encoding the same protein may have different numbers; e.g., the S glycoprotein of IBV and MHV is encoded by mRNAs 2 and 3, respectively. However, this helps to highlight a major difference.

When a protein has a name and an acronym, e.g., spike S, the corresponding mRNA can be referred to as mRNA 2 (S). It might be useful to label figures in this way. On other occasions, one might refer to “mRNA 2” or the S mRNA, as appropriate, depending on the context in which the mRNA is being discussed.

When “new” mRNAs are identified, the use of numbers should be continued. For example, in all strains of murine hepatitis virus examined mRNA 2 encodes, in the 5' ORF, a 30,000 molecular weight protein. Some strains, e.g., MHV-JHM, have more recently been shown to have an additional mRNA of a size intermediate between that of mRNA 2 and mRNA 3 (S) (9). This intermediate mRNA, which encodes HE, should be referred to as “mRNA 2.1.” A dash (-), not a point, should be used.

GENES/ORFs

Coronavirus mRNAs form a 3' coterminnal nested set and the sequences that are absent from the next smallest mRNA are often called the “unique regions.” Therefore, with the exception of the smallest mRNA, all the mRNAs are structurally polycistronic. However, it is believed (see (2)) that only the unique regions are translationally active. These regions may contain one or more ORFs.

Genes/ORFs are to be referred to by letters. When the corresponding protein has a name, the acronym (uppercase) should be used, e.g., S, HE. Otherwise, the gene/ORF should be referred to by the number of the mRNA, plus a letter (lowercase) when there is more than one ORF. For example, the unique region of mRNA3 of IBV has three ORFs, 3a, 3b, 3c. MHV-A59, in contrast to MHV-JHM, lacks a complete ORF encoding the HE protein and does not generate a mRNA for HE; consequently HE is not expressed. Thus, MHV-JHM has ORF 2a and gene HE (ORF 2b), and the corresponding ORFs of MHV-A59 are referred to as ORFs 2a and 2b.

If a newly investigated coronavirus is shown to have a genome organization very similar to that of an extensively studied coronavirus, the designations of the mRNAs and genes should be based as closely as possible on those established for the previously studied virus. In this way the nomenclature will help to reflect similarities.

REFERENCES

1. Siddell, S. G., Wege, H., and Ter Meulen, V., J. Gen. Virol. 64, 761–776 (1983).
2. Spaan, W., Cavanagh, D., and Horzinek, M. C., J. Gen. Virol. 69, 2939–2952 (1988).
3. Cavanagh, D., J. Gen. Virol. 53, 93–103 (1981).
4. Sturman, L. S., and Holmes, K. V., Virology 77, 650–660 (1977).
5. Sturman, L. S., Ricard, C. S., and Holmes, K. V., Virolology 56, 904–911 (1985).
6. Lutjes, W., Bredenbeek, P. J., Noten, A. F. H., Horzinek, M. C., and Spaan, W., Virolology 166, 415–422 (1988).
7. Vlasak, R., Lutjes, W., Leider, J., Spaan, W., and Palese, P., J. Virol. 62, 4686–4690 (1988).
8. Stern, D. F., and Sefton, B. M., J. Virol. 59, 22–29 (1984).
9. Shieh, C.-K., Lee, H.-J., Yokomori, K., La Monica, N., Makino, S., and Iai, M. M. C., J. Virol. 63, 3729–3736 (1989).

---

**TABLE 1**

| Acronyms for Coronavirus Structural Proteins |
|--------------------------------------------|
| Name | Acronym |
|------|---------|
| Spike glycoprotein | S |
| N-Terminal cleavage product | S1 |
| C-Terminal cleavage product | S2 |
| Hemagglutinin-esterase glycoprotein | HE |
| Integral membrane glycoprotein | M |
| Nucleocapsid protein | N |